SCHEDULE: Millennium Management Discloses 2.7% Stake in 10x Genomics
Beneficial Ownership Report
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported a 2.7% beneficial ownership stake in 10x Genomics, Inc. Class A Common Stock.
Summary
- Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported beneficial ownership of 3,060,859 shares of 10x Genomics, Inc. Class A Common Stock.
- This ownership represents 2.7% of the Class A Common Stock outstanding.
- The reporting persons hold shared voting power over 2,979,280 shares and shared dispositive power over 3,060,859 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previous ownership disclosure.
- The securities were not acquired or held for the purpose of changing or influencing control of 10x Genomics, Inc.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards the issuer's operational or financial performance.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
10x Genomics operates in the life sciences and biotechnology sector, providing instruments and consumables for genomics research. Millennium Management's disclosed stake indicates institutional investment interest in this sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Disclosure | Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander certified that the securities were not acquired or held for the purpose of changing or influencing the control of 10x Genomics, Inc. | 06/30/2025 | This statement clarifies that the reported ownership is a passive investment, not indicative of an activist stance or an intent to influence corporate governance beyond standard shareholder rights. |
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional holder provides transparency regarding the ownership structure and may be viewed as a vote of confidence by a prominent investment firm.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event requiring the filing of this statement |
| 08/11/2025 | Filing date of the Schedule 13G Amendment No. 1 |
Keywords
10x Genomics, Millennium Management, Israel A. Englander, Schedule 13G, Beneficial Ownership, Class A Common Stock, Institutional Investor, Equity Stake, Biotechnology, Genomics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.